CAS No.
[220991-32-2 (unlabeled)]
M.F.
CโโHโDโ
FโNOโ
Storage Condition
Store at refrigerator (2-8ยฐC) for long term storage
Synonyms
Robenacoxib-d5, 220991-32-2 (unlabeled)
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Robenacoxib-d5 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Robenacoxib-d5 usage and description
Robenacoxib-d5 is a deuterated form of the nonsteroidal anti-inflammatory drug (NSAID), robenacoxib. It is commonly used in veterinary medicine for the treatment of pain and inflammation associated with osteoarthritis and postoperative pain in dogs and cats.
Chemically, robenacoxib-d5 is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in the production of prostaglandins that cause pain and inflammation. By inhibiting COX-2, robenacoxib-d5 reduces pain and inflammation without affecting the production of prostaglandins involved in normal physiological processes.
Robenacoxib-d5 is administered orally in tablet form and is rapidly absorbed into the bloodstream, with peak plasma concentrations reached within 1-2 hours. It has a half-life of approximately 4 hours in dogs and 2.5 hours in cats.
As with all NSAIDs, robenacoxib-d5 carries a risk of adverse effects, particularly gastrointestinal ulceration and bleeding, as well as renal and hepatic toxicity. It should not be used in animals with a history of sensitivity to NSAIDs, or those with pre-existing renal or hepatic disease. Careful monitoring is recommended during treatment with robenacoxib-d5, and it should only be used under the guidance of a licensed veterinarian.